Evidence map›Paper›PMID 22027100›Full record

ArticleEuropean journal of medicinal chemistry2011

One-pot synthesis and biological evaluation of 2-pyrrolidinyl-4-amino-5-(3',4',5'-trimethoxybenzoyl)thiazole: a unique, highly active antimicrotubule agent.

Romeo Romagnoli, Pier Giovanni Baraldi, Carlota Lopez Cara, Maria Kimatrai Salvador, Roberta Bortolozzi, Giuseppe Basso, Giampietro Viola, Jan Balzarini, Andrea Brancale, Xian-Hua Fu and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in European journal of medicinal chemistry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 6 countries.

Romeo RomagnoliDipartimento di Scienze Farmaceutiche, Università di Ferrara, Via Fossato di Mortara 17-19, 44121 Ferrara, Italy. rmr@unife.it
Pier Giovanni Baraldi
Carlota Lopez Cara
Maria Kimatrai Salvador
Roberta Bortolozzi
Giuseppe Basso
Giampietro Viola
Jan Balzarini
Andrea Brancale
Xian-Hua Fu
Jun Li
Su-Zhan Zhang
Ernest Hamel
University of Ferrara · ITUniversity of Padua · ITZhejiang University · CNCardiff University · GBNational Institutes of Health · USRega Institute for Medical Research · BE

Funding

Intramural NIH HHS Z99 CA999999NCI NIH HHS Y99 CA999999
6 · The paper itself

Abstract

A wide variety of small molecules with diverse molecular scaffolds inhibit microtubule formation. In this article we report a one-pot procedure for the preparation of a novel 2-(N-pyrrolidinyl)-4-amino-5-(3',4',5'-trimethoxybenzoyl)thiazole in which the size of the substituent at the C-2 position of the thiazole ring plays an essential role in compound activity. The most active agent (3f) inhibited at submicromolar concentrations the growth of tumor cell lines. It also inhibited tubulin polymerization with an activity quantitatively similar to that of CA-4, and treatment of HeLa cells resulted in their arrest at the G2-M phase of the cell cycle. Furthermore, 3f was effective against multidrug resistant cancer cells and inhibited the growth of the HT-29 xenograft in a nude mouse model. This indicated that 3f is a promising new antimitotic agent with encouraging preclinical potential.

Indexed as

AnimalsAntineoplastic AgentsCaspase 3Cell Line, TumorCell ProliferationFemaleG2 PhaseHeLa CellsHumansMiceMice, Inbred BALB CMice, NudeNeoplasmsThiazolesTubulinTubulin ModulatorsAntineoplastic AgentsCaspase 3ThiazolesTubulinTubulin Modulators

Identifiers

PMID22027100
PMCPMC3230238
OpenAlexW2027745162

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.